Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma

Bone Marrow Transplantation

Volumn 43, Issue 1, 2009, Pages 37-42

  Yusuf, R Z ^a   Dey, B ^a   Yeap, B Y ^a   McAfee, S ^a   Attar, E ^a   Sepe, P S ^a   Dube, C ^a   Spitzer, T R ^a   Ballen, K K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; BLOOD TRANSFUSION; CANCER RELAPSE; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HEART ATRIUM FIBRILLATION; HERPES ZOSTER; HUMAN; INTERSTITIAL LUNG DISEASE; LARGE CELL LYMPHOMA; LOW DRUG DOSE; MALE; MANTLE CELL LYMPHOMA; MORTALITY; MUCOSA INFLAMMATION; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SEIZURE; STAPHYLOCOCCUS INFECTION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; VEIN OCCLUSION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING;

EID: 58649102291     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.298     Document Type: Article

References (30)

1. Bertini M, Boccomini C, Calvi R. The influence of advanced age on the treatment and prognosis of diffuse large cell lymphoma. Clin Lymphoma 2001; 1: 278-284.
2. Thieblemont C, Coiffier B. Lymphoma in older patients. J Clin Oncol 2007; 25: 1916-1923.
3. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Group d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23 4117-4126.
4. Haberman TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB et al. Rituximab-CHOP vs CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121-3127.
5. Philip T, Armitage J, Spitzer G, Chauvin F, Jagannath S, Cahn JY. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316 1493-1498.
6. Philip T, Guglielmi C, Hagenbeck A, Somers R, van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's Lymphoma. N Engl J Med 1995; 333: 1540-1545.
7. Buadi FK, Micallef IN, Ansell SM, Porrata LF, Dispenzieri A, Elliot MA et al. Autologous hematopoetic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 2006; 37: 1017-1022.
8. Jantunen E, Iala M, Juvonen E, Leppa S, Keskinen L, Vasala K et al Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: A nation-wide analysis. Bone Marrow Transplant 2006; 34: 367-372.
9. Bitran JD, Klein L, Link D, Kosirog-Glowacki J, Stewart C, Raack D et al. High-dose myeloablative therapy and autologous peripheral blood progenitor transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma. Biol Blood Marrow Transplant 2003; 9: 383-388.
10. Jantunen E. Autologous stem cell transplantation beyond 60 years of age. Bone Marrow Transplant 2006; 38: 715-720.
11. Mileshkin LR, Seymour JF, Wolf MM, Januszewicz EH, Joyce P, Prince HM. Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leukemia and Lymphoma 2005; 46: 1575-1579.
12. Aggarwal C, Gupta S, Vaughan WP, Saylors GB, Salzman DE, Katz RO et al. Improved outcomes in intermediate-and highrisk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant 2006; 12: 770-777. Bl.
13. Williams CB, Day SD, Reed MD, Copelan EA, Bechtel T, Leather HL et al Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Biol Blood Marrow Transplant 2004; 10: 614-623.
14. Toor AA, Ayers J, Strupeck J, Parthasarathy M, Creech S, Rodriguez T et al. Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma. Br J Hematol 2004; 124: 769-776.
15. Kiss TL, Panzarella T, Messner HA, Meharchand J, Reddy V, Schimmer AD et al. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2003; 31: 73-78.
16. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
17. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M et al. International Consensus Conference on High- Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: Report of the jury. J Clin Oncol 1999; 17: 423-429.
18. Dey BR, Shaffer J, Yee AJ, McAfee S, Caron M, Power et al. Comparison of outcomes after transplantation peripheral blood stem cells vs bone marrow following an HLA identical nonmyeloablative conditioning regimen. Bone Marrow Transplant 2007; 40: 19-27.
19. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem cell support. New Engl J Med 2004; 350: 1287-1295.
20. Tiwari D, Gao F, Adkins DR, Vij R, DiPersio JF, Khoury HJ. Prognostic significance of early lymphocyte recovery after post-autografting administration of GM-CSF in nonHodgkin's lymphoma. Bone Marrow Transplantation 2007; 40: 671-675.
21. Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: Allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality than autologous transplantation. Bone Marrow Transplant 2003; 31: 667-678.
22. Snyder MJ, Johnson DB, Daly MB, Giguere JK, Harman GH, Harden EA et al. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: A dose-finding study. Bone Marrow Transplant 1994; 14: 595-600.
23. Horwitz S M, Horning SJ. Rituximab in stem cell transplantation for aggressive lymphoma. Curr Hematol Rep 2004; 3: 227-229.
24. Fernandez HP, Escalon MP, Pereira D, Lazarus HM. Autotransplant conditioning regimens for aggressive lymphoma: Are we on the right track? Bone Marrow Transplant 2007; 40: 505-512.
25. Spitzer TR, Ambinder RF, Lee JY, Kaplan LD, Wachsman W, Straus DJ et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium Study. Biol Blood Marrow Transplant 2008; 14: 59-66.
26. Gopal AK, Gooley TA, Golden JB,Maloney DG, Bensinger WI, Petersdorf SH et al. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for nonHodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant 2001; 27: 593-599.
27. Seshadri T, Kuruvilla J, Crump M, Keating A. Salvage therapy for relapsed/refractory diffuse large B cell lymphoma. Biol Blood Marrow Transplant 2008; 14: 259-267.
28. Kim JG, Sohn SK, Chae YS, Yang DH, Lee JJ, Kim HJ. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2007; 40: 919-924.
29. Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 2005; 35: 233-241.
30. Zver S, Zadnik V, Bunc M, Rogel P, Cerneic P, Kozelj M. Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int J Hematol 2007; 85: 408-414.